Precigen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Precigen, Inc. - overview
Established
1998
Location
Germantown, MA, US
Primary Industry
Biotechnology
About
Precigen, Inc. is a US-based biopharmaceutical company focused on precision medicine aimed at developing innovative treatments for unmet medical needs, specializing in immuno-oncology, autoimmune disorders, and infectious diseases. Founded in 1998 in Germantown, US, Precigen, Inc. specializes in advanced biopharmaceutical technologies.
The company has undergone strategic shifts to enhance its focus on precision medicine. It has raised USD 75. 00 mn in its latest funding round, a Private Placement/Follow on, bringing its total funding to USD 75. 00 mn.
Precigen was part of Intrexon Corporation's portfolio until recently, which has influenced its operational strategies. Precigen, Inc. develops innovative biopharmaceuticals, including its core product, PAPZIMEOS (zopapogene imadenovec-drba), a subcutaneous injection targeting specific patient conditions. The company leverages advanced gene and cell therapies to deliver next-generation treatments primarily in North America, aimed at healthcare providers, hospitals, and specialty clinics.
In the most recent year, Precigen reported a revenue of USD 3. 93 mn with an EBITDA of USD -130. 50 mn. The revenue is generated from direct sales of its products, including PAPZIMEOS, through agreements with healthcare providers.
Precigen plans to utilize recent funding to establish exclusive channel collaborations, enhance its technology platforms, and expand its sales and marketing efforts. The company is focusing on launching new products and entering additional markets, particularly targeting regions with high demand for innovative therapies by the end of 2024.
Current Investors
Third Security, Sandbox Industries
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.precigen.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Precigen, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 23,760,000 | 71,930,000 | 173,605,000 | 190,926,000 | 230,981,000 | 160,574,000 | 90,722,000 | 103,178,000 | 103,873,000 | 26,909,000 | - | - | - |
| % Revenue Growth (YoY) | - | 202.7% | 141.4% | 10.0% | 21.0% | (30.5%) | (43.5%) | 13.7% | 0.7% | (74.1%) | - | - | - |
| EBITDA (USD) | (50,102,000) | (58,190,000) | (128,479,000) | (99,524,000) | (106,334,000) | (473,269,000) | (180,321,000) | (69,786,000) | (64,325,000) | (64,129,000) | - | - | - |
| Operating Income (USD) | (58,023,000) | (69,962,000) | (146,864,000) | (125,166,000) | (137,890,000) | (505,610,000) | (204,212,000) | (86,603,000) | (79,318,000) | (75,726,000) | - | - | - |
| Operating Margin | (244.2%) | (97.3%) | (84.6%) | (65.6%) | (59.7%) | (314.9%) | (225.1%) | (83.9%) | (76.4%) | (281.4%) | - | - | - |
| % EBITDA Margin | (210.9%) | (80.9%) | (74.0%) | (52.1%) | (46.0%) | (294.7%) | (198.8%) | (67.6%) | (61.9%) | (238.3%) | - | - | - |
| NET Income (USD) | (40,908,000) | (85,616,000) | (87,994,000) | (190,274,000) | (126,820,000) | (514,706,000) | (323,916,000) | (170,521,000) | (92,166,000) | 28,317,000 | - | - | - |
| % Net Margin | (172.2%) | (119.0%) | (50.7%) | (99.7%) | (54.9%) | (320.5%) | (357.0%) | (165.3%) | (88.7%) | 105.2% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.